On March 19, 2025 Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, reported a live webcast at 10:00am CET on Wednesday 26 March 2025 (Press release, Circio, MAR 19, 2025, View Source [SID1234651254]). In the webcast, Circio management will provide a corporate update and present the latest developments for the circVec platform technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webcast will include an overview of ongoing testing with the novel circVec 3.0 generation, AAV and non-viral gene therapy vector development, and tissue-specific circVec expression data in vivo, as well as an outlook on experimental plans and milestones.
The corporate section will cover Circio´s 2024 financial results (unaudited) and provide an update on financing and business development activities for 2025.
Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal
Time: 10:00 CET on 26 March 2025
click here to access the Teams webcast
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ
Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#
Questions can be submitted in advance by email to Erik D Wiklund: [email protected] or directly in the live webcast.